iCad Inc.

17.54-0.2500-1.41%Vol 97.69K1Y Perf 94.75%
Apr 19th, 2021 12:05 DELAYED
BID17.51 ASK17.58
Open17.61 Previous Close17.79
Pre-Market- After-Market-
 - -%  - -
Target Price
24.60 
Analyst Rating
Strong Buy 1.33
Potential %
40.49 
Finscreener Ranking
★★★+     53.13
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★     46.53
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★+     50.70
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Market Cap437.06M 
Earnings Rating
Sell
Price Range Ratio 52W %
70.27 
Earnings Date
10th May 2021

Today's Price Range

17.3317.77

52W Range

8.3221.44

5 Year PE Ratio Range

-8.00-3.10

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Sell
Performance
1 Week
-4.10%
1 Month
-6.17%
3 Months
36.43%
6 Months
89.05%
1 Year
94.75%
3 Years
457.68%
5 Years
261.59%
10 Years
206.72%

TickerPriceChg.Chg.%
ICAD17.54-0.2500-1.41
AAPL134.11-0.0500-0.04
GOOG2 292.91-4.8500-0.21
MSFT258.44-2.3000-0.88
XOM56.22-0.4400-0.78
WFC44.020.18000.41
JNJ162.820.58000.36
FB302.04-4.1400-1.35
GE13.35-0.0400-0.30
JPM153.08-0.2200-0.14
ValuationValueIndustryS&P 500US Markets
-22.00
15.29
19.25
21.00
-79.30
-0.32
21.94
1.23
448.30M
Forward PE206.11
PEG-1.10
Financial StrengthValueIndustryS&P 500US Markets
2.20
2.50
0.21
0.29
-45.70
Leverage Ratio 1.80
ProfitabilityValueIndustryS&P 500US Markets
71.90
-57.90
-56.00
-36.50
-20.15
RevenueValueIndustryS&P 500US Markets
23.15M
0.93
4.28
-0.86
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.08-0.0625.00
Q03 2020-0.12-0.0833.33
Q02 2020-0.16-0.1225.00
Q01 2020-0.10-0.20-100.00
Q04 2019-0.12-0.1016.67
Q03 2019-0.10-0.100.00
Q02 2019-0.10-0.0910.00
Q01 2019-0.15-0.0753.33
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.09-12.50Negative
6/2021 QR-0.06-20.00Negative
12/2021 FY-0.190.00-
12/2022 FY0.09-30.77Negative
Next Report Date10th May 2021
Estimated EPS Next Report-0.09
Estimates Count3
EPS Growth Next 5 Years %20.00
Volume Overview
Volume97.69K
Shares Outstanding24.92M
Trades Count938
Dollar Volume9.98M
Avg. Volume208.64K
Avg. Weekly Volume155.30K
Avg. Monthly Volume204.55K
Avg. Quarterly Volume221.97K

iCad Inc. (NASDAQ: ICAD) stock closed at 17.79 per share at the end of the most recent trading day (a -3.94% change compared to the prior day closing price) with a volume of 122.79K shares and market capitalization of 437.06M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Healthcare Providers & Services industry, Healthcare sector and employs 138 people. iCad Inc. CEO is Michael Klein.

The one-year performance of iCad Inc. stock is 94.75%, while year-to-date (YTD) performance is 34.77%. ICAD stock has a five-year performance of 261.59%. Its 52-week range is between 8.32 and 21.44, which gives ICAD stock a 52-week price range ratio of 70.27%

iCad Inc. currently has a PE ratio of -22.00, a price-to-book (PB) ratio of 15.29, a price-to-sale (PS) ratio of 19.25, a price to cashflow ratio of 21.00, a PEG ratio of 2.32, a ROA of -34.86%, a ROC of -59.92% and a ROE of -97.71%. The company’s profit margin is -20.15%, its EBITDA margin is -56.00%, and its revenue ttm is $23.15 Million , which makes it $0.93 revenue per share.

Of the last four earnings reports from iCad Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.09 for the next earnings report. iCad Inc.’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for iCad Inc. is Strong Buy (1.33), with a target price of $24.6, which is +40.49% compared to the current price. The earnings rating for iCad Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

iCad Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

iCad Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.67, ATR14 : 1.37, CCI20 : -110.19, Chaikin Money Flow : -0.10, MACD : 0.47, Money Flow Index : 45.66, ROC : -8.96, RSI : 49.31, STOCH (14,3) : 13.30, STOCH RSI : 0.36, UO : 38.26, Williams %R : -86.70), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of iCad Inc. in the last 12-months were: Andrew H. Sassine (Sold 100 000 shares of value $980 631 ), R. Scott Areglado (Option Excercise at a value of $90 000), R. Scott Areglado (Sold 20 000 shares of value $232 431 ), Stacey Stevens (Option Excercise at a value of $293 165), Stacey Stevens (Sold 96 432 shares of value $1 058 437 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
2 (66.67 %)
2 (66.67 %)
Moderate Buy
1 (33.33 %)
1 (33.33 %)
1 (33.33 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.33
Strong Buy
1.33
Strong Buy
1.33

iCad Inc.

icad Inc provides cancer detection, radiation therapy and workflow solutions, primarily computer-aided detection and workflow solutions for breast, prostate and colorectal cancers. Its products include powerlook tomo detection, powerlook density assessment, and vera look. The firm has also developed a technology namely Xoft Axxent electronic brachytherapy system used in the treatment of non-melanoma skin cancer, early-stage breast cancer, and gynecological cancers.

CEO: Michael Klein

Telephone: +1 603 882-5200

Address: 98 Spit Brook Road, Nashua 03062, NH, US

Number of employees: 138

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

46%54%

Bearish Bullish

50%50%

Bearish Bullish

52%48%

News

Stocktwits